Newsletter
We send out weekly newsletters to our members about announcements, event information, and what YGCC is reading blog. You can find our past blog below.
Please subscribe to our newsletter now to keep track of the latest content!
What YGCC is Reading #599
Big Pharma’s Race for In Vivo CAR-T Innovation
Eli Lilly’s $7 billion acquisition of Kelonia Therapeutics reflects a growing race among pharma companies to secure in vivo CAR-T technology, which could transform cancer treatment by enabling the body to create its own engineered immune cells. This approach promises to be faster, cheaper, and more scalable than traditional CAR-T therapies.
The deal is part of a broader surge in acquisitions, as major firms compete for limited biotech targets in this emerging field. While the technology holds huge potential—including applications beyond cancer—there are still risks around effectiveness, competition, and long-term success.
Questions:
-
Are these large biotech acquisitions a smart long-term investment or a risky trend?
-
Could in vivo CAR-T therapies make advanced treatments more accessible globally?
Image adapted from Fierce Biotech.